Biomarker

Articles

• SLCO1B3
  7 December 2007

  Uptake and export transporters SLCOs are involved in the removal of endogenous and xenobiotic substances from blood by the liver.
  Pathology
  Carcinomas
  Human liver-specific organic anion transporter-2 (LST-2/OATP8/SLCO1B3) has been demonstrated to be expressed in various gastrointestinal carcinomas and also to play pivotal roles in the uptake of a wide variety of both endogenous and exogenous anionic compounds, including bile acids, conjugated steroids and hormones, into hepatocytes in (...)

• SOX2
  13 May 2005

  SRY-box 2, SRY-related HMG-box gene 2

• NKX3A
  31 January 2007

  NKX3-1
  Definition: The homeodomain-containing transcription factor NKX3A is a putative prostate tumor suppressor that is expressed in a largely prostate-specific and androgen-regulated manner.
  NKX3.1 is a prostatic tumor suppressor gene located on chromosome 8p.
  Although most studies have shown that staining for NKX3.1 protein is positive in the majority of primary prostatic adenocarcinomas, it has been shown to be downregulated in many high-grade prostate cancers, and completely lost in (...)

• BIRC4
  23 August 2004

  XIAP

• HRPT2
  11 November 2003

  parafibromin

• L1CAM
  21 November 2003

  neural cell recognition molecule L1

• PIK3CA
  9 September 2004

  Definition: PI3K subunit p110alpha (PIK3CA) is a subunit of PI3Ks. The phosphatidylinositol 3-kinases (PI3Ks) are known regulators of cellular growth and proliferation.
  Phosphoinositide-3-kinase catalytic alpha polypeptide (PIK3CA) encodes the p110α subunit of the mitogenic signaling protein phosphoinositide 3-kinase (PI3K).
  PIK3CA mutations in the helical binding domain and the catalytic subunit of the protein have been associated with tumorigenesis and treatment resistance in various (...)

• CASR
  17 March 2011

  Pathology
  Ca(2+) is a chemopreventive agent for colon cancer.
  Ion transport systems are often altered in human cancer.
  CpG islands are densely methylated in cancer cell lines with reduced CASR mRNA expression.
  Treatment with a demethylating agent, 5-aza-2’-deoxycytidine, and/or a histone deacetylase inhibitor, trichostatin A, restores CASR expression in the cancer cell lines.
  Disruption of CASR expression in CASR-unmethylated HCT-8 cells blocsd the enhancing effect of Ca(2+) on the (...)